Cuprina and Aiodine Form Joint Venture to Develop and Market Novel Iodine-Based Wound Care Therapy

Cuprina Holdings has formed a joint venture with Aiodine Laboratory to develop and market a novel iodine-based solution for wound care therapy. The solution works by penetrating pathogens and attacking their structures, causing damage and leading to death or destruction. Initial applications will focus on antiseptic wound care, disinfectants, and daily home-use antiseptics, with additional opportunities under evaluation in personal care, oral hygiene, and veterinary applications. The companies plan to commence clinical studies in 2026 to achieve regulatory approvals.